# Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

> **NCT05069129** · PHASE1,PHASE2 · UNKNOWN · sponsor: **National Vaccine and Serum Institute, China** · enrollment: 1848 (estimated)

## Conditions studied

- COVID-19 Pneumonia
- Coronavirus Infections

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
- **BIOLOGICAL:** Inactivated COVID-19 vaccine (Vero cells)
- **BIOLOGICAL:** 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)

## Key facts

- **NCT ID:** NCT05069129
- **Lead sponsor:** National Vaccine and Serum Institute, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-14
- **Primary completion:** 2023-12
- **Final completion:** 2024-02
- **Target enrollment:** 1848 (ESTIMATED)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05069129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05069129, "Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05069129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*